FIGURE 1-1 Constraints and limitations of the four-part life cycle of the pharmaceutical drug benefit–risk assessment process.
SOURCE: Adapted from Jeffrey Leiden’s presentation.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
1 Introduction ."
Understanding the Benefits and Risks of Pharmaceuticals: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: